Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant for Growth Hormone Excess in McCune-Albright Syndrome
NCT00017927Phase 3Completed
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Jun 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pegvisomant in McCune-Albright syndrome (MAS), sponsored by National Institute of Dental and Craniofacial Research. Started Jun 2001; status: completed.
02
Drugs
pegvisomant
03
Conditions
McCune-Albright syndrome (MAS)
Beyond the preview
Go deeper on NCT00017927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017927.